Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MT-2301
- Development stage
- Phase 2
- Lead developer
- Mitsubishi Tanabe Pharma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
MT-2301 is a conjugate vaccine developed by Mitsubishi Tanabe Pharma Corporation for the prevention of invasive diseases caused by *Haemophilus influenzae* type b (Hib), such as meningitis, pneumonia, and sepsis, in infants and children. The vaccine consists of the purified capsular polysaccharide of Hib, polyribosylribitol phosphate (PRP), chemically conjugated to a tetanus toxoid carrier protein. This conjugation enhances the immune response in young infants by converting the T-cell independent polysaccharide antigen into a T-cell dependent antigen, thereby inducing high-affinity antibodies and immunological memory. MT-2301 has been evaluated in clinical trials for safety and immunogenicity, including studies where it was co-administered with other routine pediatric vaccines such as the DPT-IPV (diphtheria, pertussis, tetanus, and inactivated poliovirus) vaccine.
- Brand names
- Hib Vaccine [MTPC]
- Other names
- Haemophilus influenzae type b vaccineHib vaccine (MTPC)Lyophilized Haemophilus b Vaccine [Tanabe]
Beyond the preview
Go deeper on MT-2301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MT-2301.